News Brief: October 4, 2019 Complexa Receives Orphan Drug Designation from the FDA for CXA-10 in Pulmonary Arterial Hypertension
Press Release
, October 4th, 2019
Complexa Announces Presentation of Phase 1 Data Evaluating Lead Candidate CXA-10 as a Disease-Modifying Therapy in Pulmonary Arterial Hypertension at PHA’s 2018 International PH Conference
Press Release
, June 28th, 2019
First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension
Press Release
, February 21st, 2019
Complexa Presents Data Evaluating the Pharmacological Action of CXA-10 on Drug-metabolizing Transport Proteins at 2018 American College of Clinical Pharmacology Annual Meeting
Press Release
, September 24th, 2018
Complexa Names Theodore Danoff, MD, PhD, Chief Medical Officer
Press Release
, August 19th, 2018
Complexa Names William Leong, Vice President of Chemistry, Manufacturing and Controls
Press Release
, July 26th, 2018
First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis
Press Release
, June 1st, 2018
Appointments: News From GSK, DBV Technologies, Complexa, Synlogic And Motif Bio
Scrip, May 21st, 2018
Global Focal Segmental Glomerulosclerosis Drug Market Report 2018 by Manufacturer- Complexa Inc
Edition Analyst, May 17th, 2018
Complexa Appoints Francisco D. Salva Chief Executive Officer and President
Press Release, May 14th, 2018
- 1
- 2